Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 23, Issue 9, Pages 1279-1293Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612823666170124141806
Keywords
Anticoagulants; antidotes; antiplatelet agents; factor Xa; thrombin; thrombosis
Categories
Ask authors/readers for more resources
Thrombosis is the formation of potentially deadly blood clots in the artery (arterial thrombosis) or vein (venous thrombosis). Since thrombosis is one of the main causes of death worldwide, the development of antithrombotic agents is a global medical priority. They are subdivided into antiplatelet agents and anticoagulants. Antiplatelet agents inhibit clot formation by preventing platelet activation and aggregation, while anticoagulants primarily inhibit the coagulation cascade and fibrin formation. Therapeutics within each category differs with respect to the mechanism of action, time to onset, duration of effect and route of administration. In this review, we critically discuss their main pharmacodynamic and pharmacokinetic characteristics as well as recent advances in daily clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available